Treatment for Postpartum Dyspareunia
Initial Treatment Approach
- The American College of Obstetricians and Gynecologists recommends beginning with hormone-free vaginal lubricants and moisturizers as first-line therapy, progressing to low-dose vaginal estrogen if symptoms persist after 2-4 weeks, while simultaneously addressing any identified anatomical or muscular causes through targeted interventions 1
First-Line Treatment Options
- Water-based lubricants are recommended for use during sexual activity 1
- Daily vaginal moisturizers, such as hyaluronic acid gel or water-based gel, are recommended for ongoing maintenance 2, 1
- Silicone-based products may be considered as an alternative for longer-lasting relief 1
Second-Line Hormonal Therapy
- Low-dose vaginal estrogen is proven effective for treating vaginal dryness, itching, discomfort, and painful intercourse in postmenopausal women, and is safe and effective in postpartum women with vaginal atrophy 3
- Vaginal DHEA (prasterone) can be considered for vaginal dryness or pain, with demonstrated improvements in sexual desire, arousal, pain, and overall sexual function 3
Advanced Interventions
- Vaginal dilators may be considered for patients with pain during sexual activity, though evidence for effectiveness is limited 3, 1
- Cognitive behavioral therapy (CBT) has been shown effective at improving sexual functioning 3
- Integrative therapies, including yoga and meditation, may be helpful 3
Epidemiology and Prevalence
- Dyspareunia affects 35% of postpartum women overall, with 43% experiencing it at 2-6 months postpartum, 22% at 6-12 months, and 40% at 12-24 months 4, 5, 6
- Even women with intact perineum have 15% prevalence at 6 months and 16% at 12 months 4
Psychological Factors
- Postpartum depression (14% prevalence) and anxiety (16% prevalence) commonly coexist and impact sexual function, and should be screened for 4, 7
Treatment Effectiveness
- Regular assessment of treatment response is essential, as dyspareunia may be part of broader sexual dysfunction affecting up to 80-91% of women at 12 months postpartum 5